Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MMP-9 and CXCL8/IL-8 are potential therapeutic targets in epidermolysis bullosa simplex.

PloS one - 1 Jan 2013

Lettner Thomas, Lang Roland, Klausegger Alfred, Hainzl Stefan, Bauer Johann W, Wally Verena

Abstract excerpt

Epidermolysis bullosa refers to a group of genodermatoses that affects the integrity of epithelial layers, phenotypically resulting in severe skin blistering. Dowling-Meara, the major subtype of epidermolysis bullosa simplex, is inherited in an autosomal dominant manner and can be caused by mutations in either the keratin-5 (K5) or the keratin-14 (K14) gene. Currently, no therapeutic approach is known, and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to cdc42 GTP-Binding Protein
Share to Epidermolysis Bullosa Simplex

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Interleukin-1beta

Share to Interleukin-8

Share to Kallikreins

Share to Keratins

Share to Matrix Metalloproteinase 9

Share to Rho Guanine Nucleotide Exchange Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 23894602
DOI: 10.1371/journal.pone.0070123
PMCID: PMC3716611

Genes

CXCL8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MMP-9 and CXCL8/IL-8 are potential therapeutic targets in epidermolysis bullosa simplex.PMID 23894602Read ↗

Pathological Mechanisms Involved in Epidermolysis Bullosa Simplex: Current Knowledge and Therapeutic Perspectives.Semantic proximity Read ↗

Newer treatment modalities in epidermolysis bullosaSemantic proximity Read ↗

Keratins and epidermolysis bullosa simplexSemantic proximity Read ↗

Whole-transcriptome gene expression profiling in an epidermolysis bullosa simplex Dowling-Meara model keratinocyte cell line uncovered novel, potential therapeutic targets and affected pathways.Semantic proximity Read ↗

Treatment of Epidermolysis Bullosa and Future Directions: A ReviewSemantic proximity Read ↗

Epidermolysis bullosa simplex generalized severe induces a T helper 17 response and is improved by apremilast treatment.Semantic proximity Read ↗

Current topics in Epidermolysis bullosa: Pathophysiology and therapeutic challenges.Semantic proximity Read ↗

Therapies for genetic extracellular matrix diseases of the skin.Semantic proximity Read ↗

Induction of inflammatory cytokines by a keratin mutation and their repression by a small molecule in a mouse model for EBS.Semantic proximity Read ↗

EB2017-Progress in Epidermolysis Bullosa Research toward Treatment and Cure.Semantic proximity Read ↗

Epidermolysis Bullosa Simplex (Dowling-Meara Type) Is a Genetic Disease Characterized by an Abnormal Keratin-Filament Network Involving Keratins K5 and K14Semantic proximity Read ↗

Transcriptomic profiling of recessive dystrophic epidermolysis bullosa wounded skin highlights drug repurposing opportunities to improve wound healingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.